Early results from a phase I study on orally administered tris(8-quinolinolato)gallium(III) (FFC11, KP46) in patients with solid tumors - A CESAR study (Central European Society for Anticancer Drug Research - EWIV)

Ralf-Dieter Hofheinz; Christian Dittrich; Michael Jakupec; Anne Drescher; Ulrich Jaehde; Margit Gneist; Nikolai Graf v. Keyserlingk; Bernhard Keppler; Andreas Hochhaus

Early results from a phase I study on orally administered tris(8-quinolinolato)gallium(III) (FFC11, KP46) in patients with solid tumors - A CESAR study (Central European Society for Anticancer Drug Research - EWIV)

Ralf-Dieter Hofheinz, Christian Dittrich, Michael Jakupec, Anne Drescher, Ulrich Jaehde, Margit Gneist, Nikolai Graf v. Keyserlingk, Bernhard Keppler, Andreas Hochhaus

Department of Inorganic Chemistry

Publications: Contribution to journal › Article › Peer Reviewed

Original language	English
Pages (from-to)	590-591
Number of pages	2
Journal	International Journal of Clinical Pharmacology and Therapeutics
Volume	43
Issue number	12
Publication status	Published - 2005
Event	CESAR-Symposium "Novel Approaches for the Discovery and the Development of Anticancer Agents" - Wien, Austria Duration: 7 Jul 2005 → 9 Jul 2005

Austrian Fields of Science 2012

301206 Pharmacology

Access to Document

http://www.scopus.com/scopus/inward/record.url?eid=2-s2.0-29444456122&partnerID@&rel=R5.6.0

Cite this

Hofheinz, R.-D., Dittrich, C., Jakupec, M., Drescher, A., Jaehde, U., Gneist, M., Keyserlingk, N. G. V., Keppler, B., & Hochhaus, A. (2005). Early results from a phase I study on orally administered tris(8-quinolinolato)gallium(III) (FFC11, KP46) in patients with solid tumors - A CESAR study (Central European Society for Anticancer Drug Research - EWIV). International Journal of Clinical Pharmacology and Therapeutics, 43(12), 590-591. http://www.scopus.com/scopus/inward/record.url?eid=2-s2.0-29444456122&partnerID@&rel=R5.6.0

Hofheinz, Ralf-Dieter ; Dittrich, Christian ; Jakupec, Michael et al. / Early results from a phase I study on orally administered tris(8-quinolinolato)gallium(III) (FFC11, KP46) in patients with solid tumors - A CESAR study (Central European Society for Anticancer Drug Research - EWIV). In: International Journal of Clinical Pharmacology and Therapeutics. 2005 ; Vol. 43, No. 12. pp. 590-591.

@article{7e183c0b4349409dbc4d00512f5d18f2,

title = "Early results from a phase I study on orally administered tris(8-quinolinolato)gallium(III) (FFC11, KP46) in patients with solid tumors - A CESAR study (Central European Society for Anticancer Drug Research - EWIV)",

author = "Ralf-Dieter Hofheinz and Christian Dittrich and Michael Jakupec and Anne Drescher and Ulrich Jaehde and Margit Gneist and Keyserlingk, \{Nikolai Graf v.\} and Bernhard Keppler and Andreas Hochhaus",

note = "12.02.2008: Datenanforderung 2112 (Import Sachbearbeiter) 09.02.2010: Datenanforderung UNIVIS-DATEN-DAT.RA-2 (Import Sachbearbeiter); CESAR-Symposium {"}Novel Approaches for the Discovery and the Development of Anticancer Agents{"} ; Conference date: 07-07-2005 Through 09-07-2005",

year = "2005",

language = "English",

volume = "43",

pages = "590--591",

journal = "International Journal of Clinical Pharmacology and Therapeutics",

issn = "0946-1965",

publisher = "DUSTRI-VERLAG DR KARL FEISTLE",

number = "12",

}

Hofheinz, R-D, Dittrich, C, Jakupec, M, Drescher, A, Jaehde, U, Gneist, M, Keyserlingk, NGV, Keppler, B & Hochhaus, A 2005, 'Early results from a phase I study on orally administered tris(8-quinolinolato)gallium(III) (FFC11, KP46) in patients with solid tumors - A CESAR study (Central European Society for Anticancer Drug Research - EWIV)', International Journal of Clinical Pharmacology and Therapeutics, vol. 43, no. 12, pp. 590-591. <http://www.scopus.com/scopus/inward/record.url?eid=2-s2.0-29444456122&partnerID@&rel=R5.6.0>

Early results from a phase I study on orally administered tris(8-quinolinolato)gallium(III) (FFC11, KP46) in patients with solid tumors - A CESAR study (Central European Society for Anticancer Drug Research - EWIV). / Hofheinz, Ralf-Dieter; Dittrich, Christian; Jakupec, Michael et al.
In: International Journal of Clinical Pharmacology and Therapeutics, Vol. 43, No. 12, 2005, p. 590-591.

Publications: Contribution to journal › Article › Peer Reviewed

TY - JOUR

T1 - Early results from a phase I study on orally administered tris(8-quinolinolato)gallium(III) (FFC11, KP46) in patients with solid tumors - A CESAR study (Central European Society for Anticancer Drug Research - EWIV)

AU - Hofheinz, Ralf-Dieter

AU - Dittrich, Christian

AU - Jakupec, Michael

AU - Drescher, Anne

AU - Jaehde, Ulrich

AU - Gneist, Margit

AU - Keyserlingk, Nikolai Graf v.

AU - Keppler, Bernhard

AU - Hochhaus, Andreas

N1 - 12.02.2008: Datenanforderung 2112 (Import Sachbearbeiter) 09.02.2010: Datenanforderung UNIVIS-DATEN-DAT.RA-2 (Import Sachbearbeiter)

PY - 2005

Y1 - 2005

M3 - Article

SN - 0946-1965

VL - 43

SP - 590

EP - 591

JO - International Journal of Clinical Pharmacology and Therapeutics

JF - International Journal of Clinical Pharmacology and Therapeutics

IS - 12

T2 - CESAR-Symposium "Novel Approaches for the Discovery and the Development of Anticancer Agents"

Y2 - 7 July 2005 through 9 July 2005

ER -

Hofheinz RD, Dittrich C, Jakupec M, Drescher A, Jaehde U, Gneist M et al. Early results from a phase I study on orally administered tris(8-quinolinolato)gallium(III) (FFC11, KP46) in patients with solid tumors - A CESAR study (Central European Society for Anticancer Drug Research - EWIV). International Journal of Clinical Pharmacology and Therapeutics. 2005;43(12):590-591.